Key result
Targeting serotonin synthesis or signaling shows promise for developing novel PAH therapies.
Why the study?
Serotonin synthesis is elevated in PAH and associated with its pathologies, making targeting serotonin synthesis or signaling a promising approach for novel therapies.
This review highlights the pathogenic role of serotonin in pulmonary arterial hypertension and suggests targeting its synthesis or signaling as a promising therapeutic strategy.
Answers are grounded in this paper and cite their sources.
Should not yet alter PAH management; leaves open whether TPH1 or 5-HT1B inhibition improves outcomes in trials.
Serotonin is often referred to as a "happy hormone" as it maintains good mood, well-being, and happiness. It is involved in communication between nerve cells and plays a role in sleeping and digestion. However, too much serotonin can have pathogenic effects and serotonin synthesis is elevated in pulmonary artery endothelial cells from patients with pulmonary arterial hypertension (PAH). PAH is characterized by elevated pulmonary pressures, right ventricular failure, inflammation, and pulmonary vascular remodeling; serotonin has been shown to be associated with these pathologies. The rate-limiting enzyme in the synthesis of serotonin in the periphery of the body is tryptophan hydroxylase 1 (TPH1). TPH1 expression and serotonin synthesis are elevated in pulmonary artery endothelial cells in patients with PAH. The serotonin synthesized in the pulmonary arterial endothelium can act on the adjacent pulmonary arterial smooth muscle cells (PASMCs), adventitial macrophages, and fibroblasts, in a paracrine fashion. In humans, serotonin enters PASMCs cells via the serotonin transporter (SERT) and it can cooperate with the 5-HT1B receptor on the plasma membrane; this activates both contractile and proliferative signaling pathways. The "serotonin hypothesis of pulmonary hypertension" arose when serotonin was associated with PAH induced by diet pills such as fenfluramine, aminorex, and chlorphentermine; these act as indirect serotonergic agonists causing the release of serotonin from platelets and cells through the SERT. Here the role of serotonin in PAH is reviewed. Targeting serotonin synthesis or signaling is a promising novel alternative approach which may lead to novel therapies for PAH.
No takes yet. Share an insight, caveat, or question.
MacLean et al. (2022) conducted a review in Pulmonary arterial hypertension. Targeting serotonin synthesis or signaling was evaluated. Targeting serotonin synthesis or signaling is a promising approach that may lead to novel therapies for pulmonary arterial hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: